| Project/Area Number |
15K08100
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Medical pharmacy
|
|---|
| Research Institution | Sojo University (2017)
Kumamoto University (2015-2016) |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
平田 純生 熊本大学, 薬学部附属育薬フロンティアセンター, 教授 (10432999)
成田 勇樹 熊本大学, 薬学部, 助手 (40614665)
|
|---|
| Project Period (FY) |
2015-04-01 – 2018-03-31
|
| Project Status |
Completed (Fiscal Year 2017)
|
| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2017: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2016: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2015: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
|---|
| Keywords | 腎細胞癌 / 降圧薬 / 分子標的治療薬 / 副作用軽減 / レニンアンジオテンシン / アンジオテンシン受容体拮抗薬 / スニチニブ / 抗腫瘍効果 / ARB / 腎細胞がん / 酸化ストレス |
|---|
| Outline of Final Research Achievements |
The first-line drug in renal cell carcinoma is sunitinib (SU) which is a molecular target drug. Although SU shows hypertension and proteinuria as a side effect, there is also a report that hypertension by SU is related to therapeutic effect. So, it is concerned that treatment of hypertension may hinder antitumor effect. Therefore, we evaluated the antitumor effect, hypertension and proteinuria when using SU with angiotensin II receptor antagonist (ARB) in tumor bearing mice. As a result, it was suggested that hypertension was ameliorated by using ARB olmesartan, and anticancer effect was increased. Therefore, ARB is recommended for hypertension observed in SU therapy against renal cell carcinoma.
|
